WP 1303

Drug Profile

WP 1303

Alternative Names: H-1129; WP-1303

Latest Information Update: 22 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator D. Western Therapeutics Institute
  • Developer D. Western Therapeutics Institute; Wakamoto
  • Class Antiglaucomas; Small molecules
  • Mechanism of Action HSP90 heat-shock protein modulators; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glaucoma; Ocular hypertension

Most Recent Events

  • 15 Mar 2017 D.Western Therapeutics Institute completes a phase I trial in Glaucoma and Ocular hypertension (In volunteers) in Japan
  • 02 Feb 2017 D. Western Therapeutics plans a phase II trial for Glaucoma in Japan in 2017
  • 02 Feb 2017 D. Western Therapeutics plans a phase III trial for Glaucoma in Japan in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top